Margetuximab对比曲妥珠单抗治疗经治HER2阳性晚期乳腺癌(SOPHIA):随机3期试验最终总生存结果
SOPHIA研究纳入536例经治HER2阳性晚期乳腺癌患者,随机接受Margetuximab或曲妥珠单抗联合化疗。最终总生存分析由385个预设事件触发,Margetuximab组中位OS为21.6个月,曲妥珠单抗组为21.9个月(HR 0.95,95%CI 0.77-1.17,P=0.620),未显示Margetuximab优于曲妥珠单抗。
要点
- Margetuximab组中位OS 21.6个月 vs 曲妥珠单抗组21.9个月,HR 0.95(95%CI 0.77-1.17,P=0.620),无显著差异。
- 探索性CD16A基因分型分析提示CD16A-158FF患者Margetuximab可能改善OS(HR 0.72,95%CI 0.52-1.00)。
- Margetuximab安全性特征与曲妥珠单抗相当。
核心结论
- 最终总生存分析未显示Margetuximab较曲妥珠单抗具有优势。
- 作者认为需要在不同CD16A等位基因变异的HER2阳性乳腺癌患者中开展Margetuximab研究。
研究设计与样本
- 随机3期试验SOPHIA(NCT02492711),纳入536例经治HER2阳性晚期乳腺癌患者。
- 意向治疗人群随机分配至Margetuximab 15 mg/kg静脉给药每3周一次(n=266)联合化疗,或曲妥珠单抗负荷剂量8 mg/kg后6 mg/kg静脉给药每3周一次(n=270)联合化疗。
- 主要终点为无进展生存(已报告)和总生存;最终OS分析由385个预设事件触发。
主要发现
- Margetuximab组中位OS为21.6个月(95%CI 18.89-25.07),曲妥珠单抗组为21.9个月(95%CI 18.69-24.18),HR 0.95(95%CI 0.77-1.17,P=0.620)。
- 预设探索性CD16A基因分型分析显示,CD16A-158FF患者中Margetuximab较曲妥珠单抗可能改善OS(中位OS 23.6 vs 19.2个月;HR 0.72;95%CI 0.52-1.00)。
- CD16A-158VV患者中曲妥珠单抗较Margetuximab可能改善OS(中位OS 31.1 vs 22.0个月;HR 1.77;95%CI 1.01-3.12)。
- Margetuximab安全性特征与曲妥珠单抗相当。
关键数值与推荐
- Margetuximab 15 mg/kg静脉给药每3周一次联合化疗。
- 曲妥珠单抗负荷剂量8 mg/kg后6 mg/kg静脉给药每3周一次联合化疗。
- 最终OS分析由385个预设事件触发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711), a study of margetuximab versus trastuzumab, both with chemotherapy, in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer, is reported with updated safety. Overall, 536 patients in the intention-to-treat population were randomly assigned to margetuximab (15 mg/kg intravenously once every 3 weeks; n = 266) plus chemotherapy or trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg; n = 270) plus chemotherapy. Primary end points were progression-free survival, previously reported, and OS. Final OS analysis was triggered by 385 prespecified events. The median OS was 21.6 months (95% CI, 18.89 to 25.07) with margetuximab versus 21.9 months (95% CI, 18.69 to 24.18) with trastuzumab (hazard ratio [HR], 0.95; 95% CI, 0.77 to 1.17; P = .620). Preplanned, exploratory analysis of CD16A genotyping suggested a possible improvement in OS for margetuximab in CD16A-158FF patients versus trastuzumab (median OS, 23.6 v 19.2 months; HR, 0.72; 95% CI, 0.52 to 1.00) and a possible improvement in OS for trastuzumab in CD16A-158VV patients versus margetuximab (median OS, 31.1 v 22.0 months; HR, 1.77; 95% CI, 1.01 to 3.12). Margetuximab safety was comparable with trastuzumab. Final overall OS analysis did not demonstrate margetuximab advantage over trastuzumab. Margetuximab studies in patients with human epidermal growth factor receptor 2-positive breast cancer with different CD16A allelic variants are warranted.
引用
- Rugo HS, Im SA, Cardoso F, et al. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. J Clin Oncol. 2022. PMID: 36332179. doi:10.1200/JCO.21.02937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。